Saturday, November 28, 2020 9:51:28 AM
We know that there were two gag orders regarding Total's heavily redacted but fully consummated done deal with ERHC.
Why?
Yes, those gag orders pay a very significant front and center role in halting, whether temporarily or permanently, the standard process of revocation. In fact, the gag orders could very well make ERHC achieve a historical and landmark event of resurrection from the grays to the pinks... which will surely attract many investors as such an event will be seen as the rise of ERHC.
But more important, with regard to the gag orders, is not the incredible impact they have had on the revocation process but something else entirely different.
The gag orders call attention to the significance of the Total contract with ERHC itself.
Again, I must ask, why? What is so unique, so intriguing, so compelling about the Total contract which would elicit not one but TWO gag orders by two separate litigation venues and a heavily redacted contract?
Does anyone seriously think for a moment that the gag orders and redaction occurred because the deal with Total was insignificant and much smaller than the $700k offered by Kosmos?
Seriously?
Or does Occam's razor tell us that where there's smoke, there's fire?
What we have here is more likely than not a blazing inferno of nothing but good news but kept under wraps and still uncertain due to the Kosmos contestation.
The Kosmos $700k is $.0002 a share.
But Total is $???/ share
Why aren't we trading at $ ???/ share?
Well because of that uncertainty, we are straddling somewhere between $.0002 and $???/ share.
Where is the middle of that range?
I don't know.
But my gut says that $.001 is no where near the 50 yard line.
And as we make our come back from an underdog position from grays to pinks... so too will we cross that 50 yard line and make our way to touch down.
And then?
Asses will be handed out, first come first serve.
Krombacher
Recent ERHE News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 07:31:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:06:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 05:35:35 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM